Fasıme Ozge AYGUN KAS
Research Subjects
Research Interests
Fasıme Ozge AYGUN KAS has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Emine Gencer
Private Kapadokya Hospital, Turkey
2 shared publications - Ismaıl TURKOZ
Dörtyol State Hospital, Turkey
2 shared publications - Duygu Kayar Çalılı
ANKARA YILDIRIM BEYAZIT ÜNİVERSİTESİ, TIP FAKÜLTESİ
1 shared publication - Gılman Tugce Tutkun
Izmir Bakircay University
1 shared publication - Hande İdIl Tüz
Balıkesir Ataturk City Hospital, Turkey
1 shared publication - Mehmet Ali Tüz
Balikesir University, Turkey
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Revista do Instituto de Medicina Tropical de São Paulo
- Vol. 67, e28
Tocilizumab and IVIG experience during the service follow-up in patients with severe COVID-19 pneumonia
Most SARS-CoV-2 infections are asymptomatic or cause only mild illness, but severe respiratory disease can develop, sometimes requiring oxygen support. Immunopathological damage resulting from an abnormal inflammatory response in patients with severe disease is known to be the main determinant of disease outcome. Studies show that anti-inflammatory therapies work best when used before widespread immunopathological damage has occurred. Similarly, it was thought that intravenous immunoglobulin (IVIG)—holding multiple immunomodulatory effects—would provide clinically favorable results, but recent studies suggest otherwise. Still, the literature shows few studies evaluating the efficacy of IVIG according to the time of administration and there are no studies comparing it with established treatments, such as tocilizumab. In this study, we aimed to evaluate the effects of early administration of tocilizumab and IVIG on clinical outcome in patients with severe COVID-19. Patients with progressive clinical and laboratory deterioration who received tocilizumab or IVIG between 07/2020 and 10/2020 in a public hospital ward were retrospectively evaluated. A total of 74 patients were identified, of whom 29 (39%) received IVIG only and 26 (35%) received tocilizumab only. As a result, patients with severe COVID-19 who received IVIG in early stages of the disease did not have better clinical outcomes regarding mortality, length of hospital stay and ICU admission compared to those who received tocilizumab. Moreover, there is no data to support the use of IVIG in COVID-19 patients with severe disease, as it is associated with more severe side effects and is more expensive than tocilizumab.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Revista do Instituto de Medicina Tropical de São Paulo
- Vol. 67, e28
Open AccessTocilizumab and IVIG experience during the service follow-up in patients with severe COVID-19 pneumonia
Most SARS-CoV-2 infections are asymptomatic or cause only mild illness, but severe respiratory disease can develop, sometimes requiring oxygen support. Immunopathological damage resulting from an abnormal inflammatory response in patients with severe disease is known to be the main determinant of disease outcome. Studies show that anti-inflammatory therapies work best when used before widespread immunopathological damage has occurred. Similarly, it was thought that intravenous immunoglobulin (IVIG)—holding multiple immunomodulatory effects—would provide clinically favorable results, but recent studies suggest otherwise. Still, the literature shows few studies evaluating the efficacy of IVIG according to the time of administration and there are no studies comparing it with established treatments, such as tocilizumab. In this study, we aimed to evaluate the effects of early administration of tocilizumab and IVIG on clinical outcome in patients with severe COVID-19. Patients with progressive clinical and laboratory deterioration who received tocilizumab or IVIG between 07/2020 and 10/2020 in a public hospital ward were retrospectively evaluated. A total of 74 patients were identified, of whom 29 (39%) received IVIG only and 26 (35%) received tocilizumab only. As a result, patients with severe COVID-19 who received IVIG in early stages of the disease did not have better clinical outcomes regarding mortality, length of hospital stay and ICU admission compared to those who received tocilizumab. Moreover, there is no data to support the use of IVIG in COVID-19 patients with severe disease, as it is associated with more severe side effects and is more expensive than tocilizumab.
- 29 October 2022
- Published by Hitit University in Hitit Medical Journal
- Vol. 4 (3) , 84-88
Yoğun bakımda COVID-19 Pnömonisi olan SARS-COV-2 RT-PCR Pozitif ve Negatif Hastalarin Karşılaştırılması
Aim: We aimed to compare RT-PCR positive and RT-PCR negative patients with radiologically confirmed COVID-19 pneumonia admitted to the intensive care unit (ICU) in terms of outcome and laboratory results in the inflammation process. Material / Method: Patients who were admitted to the ICU due to respiratory failure and had typical COVID-19 pneumonia findings on thorax tomography were included in the study. Patients were grouped as RT-PCR negative and RT-PCR positive. Groups were compared for descriptive and laboratory characteristics, treatments, length of stay and outcome. Results: Lactate, D-dimer levels, and leukocyte, neutrophil counts of the RT-PCR positive group were lower than the other group (p
- 29 October 2022
- Published by Hitit University in Hitit Medical Journal
- Vol. 4 (3) , 84-88
Yoğun bakımda COVID-19 Pnömonisi olan SARS-COV-2 RT-PCR Pozitif ve Negatif Hastalarin Karşılaştırılması
Aim: We aimed to compare RT-PCR positive and RT-PCR negative patients with radiologically confirmed COVID-19 pneumonia admitted to the intensive care unit (ICU) in terms of outcome and laboratory results in the inflammation process. Material / Method: Patients who were admitted to the ICU due to respiratory failure and had typical COVID-19 pneumonia findings on thorax tomography were included in the study. Patients were grouped as RT-PCR negative and RT-PCR positive. Groups were compared for descriptive and laboratory characteristics, treatments, length of stay and outcome. Results: Lactate, D-dimer levels, and leukocyte, neutrophil counts of the RT-PCR positive group were lower than the other group (p